{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:20:52Z","timestamp":1761430852181,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.3109\/14653249.2012.698119","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T11:20:12Z","timestamp":1342524012000},"page":"773-774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Less expensive CARs?"],"prefix":"10.1016","volume":"14","author":[{"given":"John C.","family":"Riches","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3109\/14653249.2012.698119_bib0005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.3109\/14653249.2012.698119_bib0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies","volume":"14","author":"Shimasaki","year":"2012","journal-title":"Cytotherapy"},{"key":"10.3109\/14653249.2012.698119_bib0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nri2635","article-title":"Engineering lymphocyte subsets: tools, trials and tribulations","volume":"9","author":"June","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.3109\/14653249.2012.698119_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/956304","article-title":"Chimeric antigen receptor-engineered T cells for immunotherapy of cancer","author":"Cartellieri","year":"2010","journal-title":"J Biomed Biotechnol."},{"key":"10.3109\/14653249.2012.698119_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/595060","article-title":"Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia","author":"Koehler","year":"2012","journal-title":"Adv Hematol."},{"key":"10.3109\/14653249.2012.698119_bib0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/clin.1995.1048","article-title":"Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens","volume":"75","author":"Dazzi","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"10.3109\/14653249.2012.698119_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.3109\/14653249.2012.698119_bib0040","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.698119_bib0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2865.2865","article-title":"A phase I clinical trial of treatment of B-cell malignancies with autologous anti-CD19-CAR-transduced T cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.698119_bib0050","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"10.3109\/14653249.2012.698119_bib0055","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.698119_bib0060","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.698119_bib0065","first-page":"677","article-title":"Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia","volume":"20","author":"Giannopoulos","year":"2008","journal-title":"Oncol Rep"},{"key":"10.3109\/14653249.2012.698119_bib0070","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/10428190902803677","article-title":"Enhanced formation and survival of CD4 + CD25hi Foxp3 + T-cells in chronic lymphocytic leukemia","volume":"50","author":"Jak","year":"2009","journal-title":"Leuk Lymph"},{"key":"10.3109\/14653249.2012.698119_bib0075","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324912706916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324912706916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:16:22Z","timestamp":1761430582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324912706916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1465324912706916"],"URL":"https:\/\/doi.org\/10.3109\/14653249.2012.698119","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Less expensive CARs?","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3109\/14653249.2012.698119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}